



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated January 06, 2017

To,
National Stock Exchange of India Limited
Bombay Stock Exchange Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules India's Gagillapur facility completed inspection by INFARMED, Portugal -Press Release-Reg.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

With reference to the captioned subject, please find herewith a copy of Press Release issued by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED



CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)

Granules India's Gagillapur facility completed INFARMED inspection.

Hyderabad, January 06, 2017: Granules India Ltd., informs that INFARMED (Instituto Nacional da Farmácia E Do Medicamento) Portugal, had conducted a renewal inspection on the Company's facility located at Gagillapur, Telangana, India. In this respect, today the Company has received the inspection report from INFARMED with eleven (11) observations. The Gagillapur facility manufactures Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs).

The company has initiated necessary steps to address the observations of the inspection agency and will submit its response with a corrective and preventive action plan within the stipulated time. The company will also be requesting the INFARMED for re-inspection of the Gagillapur facility at the earliest.

The Company is committed to comply with all the required regulatory requirements and follow the best practices of the industry. The Company acknowledges the observations as areas of continuous improvements.